gmp
gmp

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Farxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            The designation is based on the Phase III DAPA-MI trial that will explore the efficacy and safety of Farxiga in this patient population. Acute MI is a serious condition and a known cause of heart failure (HF). Approximately seven million heart attacks occur globally each year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Farxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2020

            Details:

            The SGLT2 inhibitor dapagliflozin, when used in patients with heart failure, provided a benefit in preventing type 2 diabetes (T2D).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Farxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            Details:

            An oral presentation of data from the DAPA-HF trial showing the effect of Farxiga (dapagliflozin) on the incidence of new onset of type-2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ticagrelor,Aspirin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2020

            Details:

            The approval was based on positive results from the Phase III THEMIS trial. The trial showed a statistically significant reduction in the primary composite endpoint of MACE at 36 months with aspirin + Brilinta 60mg versus aspirin alone in patients with CAD and type-2 diabetes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Troxerutin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: STADA Production Ireland Ltd., trading as Suir Pharma Ireland

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition February 24, 2020

            Details:

            The transaction represents 15 brands including Venoruton, for venous treatment; Coldrex cold remedy; Cetebe vitamin C supplements; Mebucaine sore throat range and Tavegyl allergy brand.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Propranolol

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ATNAHS PHARMA UK LIMITED

            Deal Size: $390.0 million Upfront Cash: $350.0 million

            Deal Type: Divestment January 27, 2020

            Details:

            AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.